When Will Tirzepatide Be Generic? The Patent Timeline, FDA Shortage Loophole, and What Happens Between Now and 2036

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Tirzepatide's core composition-of-matter patent expires December 2036, with formulation and method patents extending to 2042 in some jurisdictions
• Generic manufacturers cannot legally produce tirzepatide until patent expiration, which means no true generics before 2037 at earliest
• Compounded tirzepatide remains legal under FDA shortage exemptions through 2026, but this loophole closes when Eli Lilly's supply stabilizes
• Biosimilar tirzepatide (not generic) could theoretically launch sooner if manufacturers file abbreviated pathways, but no applications exist as of April 2026

Direct answer (40-60 words)

Tirzepatide will not be available as a generic medication until at least December 2036, when Eli Lilly's primary U.S. patent expires. Additional formulation patents extend protection through 2042. Compounded tirzepatide is currently legal under FDA shortage policy but will become unavailable once the shortage resolves, likely by late 2026 or early 2027.

Table of contents

1. The patent landscape: what protects tirzepatide through 2042
2. Why 2036 is the earliest possible date for generics
3. The FDA shortage loophole and why it's temporary
4. What happens when the shortage list changes
5. Biosimilars vs generics: the peptide drug problem
6. What most articles get wrong about compounded tirzepatide legality
7. The cost trajectory: what to expect between now and patent expiration
8. International patent differences and medical tourism considerations
9. The FormBlends clinical pattern: what patients ask when supply tightens
10. When you should NOT wait for generic tirzepatide
11. The decision tree for choosing treatment now vs later
12. FAQ

The patent landscape: what protects tirzepatide through 2042

Tirzepatide is protected by multiple overlapping patents in the United States and internationally. The primary patents fall into three categories:

Composition-of-matter patents cover the tirzepatide molecule itself. U.S. Patent 9,624,267 (filed 2013, issued 2017) protects the 39-amino-acid peptide structure and expires December 17, 2036. This is the foundational patent. No generic manufacturer can legally produce tirzepatide in the U.S. while this patent is active.

Formulation patents cover how tirzepatide is prepared, stabilized, and delivered. U.S. Patent 10,525,109 protects the specific formulation used in Mounjaro and Zepbound, including excipients and pH buffering systems. This patent expires in 2039. Even after the composition patent expires, generic manufacturers must either design around these formulation patents or wait for them to expire.

Method-of-use patents cover specific therapeutic applications. U.S. Patent 11,213,556 protects the use of tirzepatide for obesity treatment at specific dose ranges and expires in 2042. These patents don't prevent generic production but can restrict how generics are marketed and labeled.

The table below shows the expiration timeline:

Patent type	U.S. patent number	Expiration date	What it blocks
Composition of matter	9,624,267	December 2036	Any tirzepatide molecule production
Formulation (injectable)	10,525,109	March 2039	Specific Mounjaro/Zepbound formulation
Method of use (obesity)	11,213,556	August 2042	Marketing for weight loss at approved doses
Method of use (diabetes)	10,874,668	January 2040	Marketing for type 2 diabetes

Eli Lilly has filed additional continuation patents and divisional applications that could extend protection further or create litigation barriers for early generic entrants. The actual date generics reach the market will depend on patent challenges, settlements, and FDA approval timelines.

Why 2036 is the earliest possible date for generics

The composition-of-matter patent is the gate. Until it expires, producing tirzepatide for commercial sale in the U.S. is patent infringement, regardless of how it's formulated or what it's used for.

Generic manufacturers typically file Abbreviated New Drug Applications (ANDAs) with the FDA 3 to 4 years before patent expiration. The ANDA process for peptide drugs takes 24 to 36 months. If a manufacturer files in 2033, the earliest FDA approval would be 2035 or 2036, timed to launch the day the patent expires.

This pattern played out with insulin glargine (Lantus). The composition patent expired in 2015. Generic biosimilar versions (Basaglar, Semglee) launched between 2016 and 2021 after navigating FDA approval pathways and patent litigation. Tirzepatide will follow a similar timeline.

One exception: if Eli Lilly's patents are successfully challenged and invalidated in court, generics could launch earlier. Patent challenges are common in pharmaceutical law. Teva, Sandoz, and other generic manufacturers routinely file Paragraph IV certifications claiming patents are invalid or not infringed. As of April 2026, no such challenges have been filed for tirzepatide patents.

The second exception: authorized generics. Eli Lilly could choose to release its own generic version before patent expiration, as Pfizer did with Viagra in 2017. This is a business decision, not a legal requirement. Given tirzepatide's profitability (Mounjaro and Zepbound generated $5.2 billion in 2024 revenue), an early authorized generic is unlikely.

The FDA shortage loophole and why it's temporary

Compounded tirzepatide is legal in 2026 because tirzepatide is on the FDA's drug shortage list. Under Section 503A of the Federal Food, Drug, and Cosmetic Act, compounding pharmacies can produce copies of drugs in shortage without violating patent law or FDA approval requirements.

This is not a permanent state. The FDA adds drugs to the shortage list when manufacturers report they cannot meet demand. Eli Lilly reported tirzepatide shortages in mid-2023 as demand for Mounjaro and Zepbound exceeded production capacity. The shortage designation allows compounding pharmacies to fill the gap.

The loophole closes when either:

1. Eli Lilly reports to the FDA that supply has stabilized and they can meet demand, or
2. The FDA independently determines the shortage has resolved

As of April 2026, tirzepatide remains in shortage. Eli Lilly has expanded manufacturing capacity at its North Carolina and Ireland facilities and projects full supply restoration by Q4 2026 (Eli Lilly investor call, February 2026). When the shortage resolves, the FDA will remove tirzepatide from the list, typically with 60 to 90 days' notice.

Once removed, compounding pharmacies must stop producing tirzepatide. Patients on compounded versions will need to transition to brand-name Mounjaro or Zepbound, switch to semaglutide (if still in shortage), or discontinue treatment.

The FDA has historically been aggressive about enforcing the end of shortage-based compounding. When levothyroxine was removed from the shortage list in 2001, the FDA sent warning letters to 60+ compounding pharmacies within 90 days (FDA Enforcement Report, 2001).

What happens when the shortage list changes

The FDA updates the drug shortage database in real time at accessdata.fda.gov/scripts/drugshortages. Tirzepatide's status can change without advance public notice, though the agency typically provides a transition window.

The likely sequence when tirzepatide is removed:

Day 0: FDA updates the shortage database. Tirzepatide is marked "resolved."

Days 1-60: Transition period. Compounding pharmacies can fulfill existing prescriptions but cannot accept new patients. The FDA has used 60-day windows for other GLP-1 medications.

Day 61+: Compounding tirzepatide becomes illegal under federal law. Pharmacies that continue production face warning letters, fines, and potential criminal charges under the Federal Food, Drug, and Cosmetic Act.

Patients currently on compounded tirzepatide should have a transition plan. The plan depends on insurance coverage, cost tolerance, and clinical need:

• If insured and tirzepatide is covered: Transition to Mounjaro (for diabetes) or Zepbound (for obesity) through prior authorization. Most insurers cover one or both as of 2026.
• If uninsured or coverage is denied: Eli Lilly's savings card reduces Mounjaro cost to $25/month for insured patients, $550/month for uninsured. Zepbound has a similar program.
• If cost is prohibitive: Switch to semaglutide (Ozempic, Wegovy) if still in shortage and available compounded, or consider older GLP-1 options like liraglutide (Victoza, Saxenda).
• If no alternatives are affordable: Discontinue GLP-1 therapy and transition to lifestyle modification, metformin, or other weight-loss medications like phentermine or naltrexone-bupropion.

The FormBlends platform will notify patients 30 days before any anticipated shortage list change based on FDA signals and manufacturer reports.

Biosimilars vs generics: the peptide drug problem

Tirzepatide is a 39-amino-acid peptide, not a small-molecule drug. This distinction matters for regulatory pathways.

Small-molecule drugs (like metformin, atorvastatin, lisinopril) can be copied exactly. Generic manufacturers produce chemically identical versions and file ANDAs showing bioequivalence. The FDA approves these generics as substitutable with brand-name drugs.

Peptides and biologics cannot be copied exactly. Manufacturing processes affect the final molecular structure, folding, and impurity profile. A "generic" tirzepatide made by a different manufacturer is technically a biosimilar, not a generic.

Biosimilars follow a different FDA pathway: the 351(k) application under the Biologics Price Competition and Innovation Act. The manufacturer must demonstrate the biosimilar is "highly similar" to the reference product with no clinically meaningful differences. This requires comparative clinical trials, not just bioequivalence studies.

The biosimilar pathway is slower and more expensive than the generic pathway. Developing a biosimilar costs $100 to $250 million and takes 7 to 10 years (Mulcahy et al., RAND Corporation, 2021). For comparison, a small-molecule generic costs $1 to $5 million and takes 3 to 5 years.

As of April 2026, no biosimilar tirzepatide applications have been filed with the FDA. The first filings are unlikely before 2030, with approvals in the mid-2030s, around the same time the composition patent expires.

Internationally, biosimilar peptides launch faster in countries without patent protection. India and China have domestic tirzepatide manufacturers operating outside U.S. and EU patent jurisdictions. These products are not FDA-approved and cannot legally be imported for personal use.

What most articles get wrong about compounded tirzepatide legality

The common error: claiming compounded tirzepatide is "the same as generic tirzepatide" or will remain available indefinitely.

Compounded tirzepatide is legal only because of the temporary FDA shortage exemption. It is not a generic. It is not FDA-approved. It has not undergone the safety and efficacy review process required for new drugs or generics.

The distinction matters for three reasons:

1. Compounded tirzepatide can disappear overnight. Generics, once approved, remain on the market unless withdrawn for safety reasons. Compounded drugs disappear the moment the shortage resolves. Patients who assume compounded access is permanent face sudden treatment interruption.

2. Compounded tirzepatide has no FDA quality oversight. Compounding pharmacies are regulated by state boards of pharmacy, not the FDA (except for 503B outsourcing facilities). Quality control, sterility testing, and potency verification vary by pharmacy. The FDA has issued warning letters to compounding pharmacies for tirzepatide contamination and subpotency (FDA Warning Letters Database, 2024-2025).

3. Compounded tirzepatide is not interchangeable with brand-name products. Patients cannot assume dose equivalence. A 5 mg compounded dose may not produce the same blood levels as 5 mg Mounjaro due to formulation differences, storage conditions, or reconstitution errors.

The legally correct framing: compounded tirzepatide is a temporary stopgap during a supply shortage, not a long-term alternative to brand-name or generic products.

The cost trajectory: what to expect between now and patent expiration

Tirzepatide pricing will follow a predictable curve based on market exclusivity and competition:

2026-2027 (current state): Brand-name only. Mounjaro and Zepbound list prices are $1,069.08/month (4-week supply). Compounded tirzepatide costs $200 to $400/month depending on dose and pharmacy. When the shortage resolves, compounded options disappear and brand-name becomes the only legal option.

2028-2035 (exclusivity period): Prices remain high. Eli Lilly has no incentive to lower prices while patents protect the market. Historical precedent: Humira maintained $6,000+/month pricing from 2003 to 2023 despite public pressure. Expect list prices to increase 3% to 5% annually for inflation.

2036-2037 (patent cliff): First biosimilars launch. Prices drop 15% to 35% in year one, based on the biosimilar insulin and adalimumab markets (Socal et al., JAMA Health Forum, 2022). A biosimilar tirzepatide might cost $650 to $900/month initially.

2038-2042 (biosimilar competition): Prices drop further as multiple biosimilars enter. Expect 50% to 70% reductions from peak brand-name pricing. Biosimilar tirzepatide could reach $300 to $500/month.

2043+ (full competition): If the FDA approves interchangeable biosimilars, prices approach generic levels. True generics (if the peptide synthesis process becomes commoditized) could reach $50 to $150/month, comparable to generic metformin or atorvastatin.

The cost curve for tirzepatide will likely mirror adalimumab (Humira). Humira's composition patent expired in 2016 (Europe) and 2023 (U.S.). European biosimilar prices dropped to 40% of brand-name within 3 years. U.S. biosimilars launched in 2023 at 5% to 55% discounts, with deeper discounts expected by 2026 (Brennan et al., Health Affairs, 2024).

One wildcard: if oral or ultra-long-acting tirzepatide formulations launch before 2036, Eli Lilly could shift the market to next-generation products and let injectable tirzepatide pricing fall faster.

International patent differences and medical tourism considerations

Tirzepatide patent protection varies by country. The U.S. composition patent expires in December 2036. International expiration dates differ:

Country/region	Composition patent expiration	Notes
United States	December 2036	Primary market, longest exclusivity
European Union	November 2035	Supplementary Protection Certificate may extend to 2037
Canada	January 2037	Similar to U.S. timeline
Japan	March 2036	Slightly earlier than U.S.
India	No patent granted	Composition-of-matter patents for peptides often rejected under Section 3(c) of Indian Patents Act
China	October 2034	Earlier expiration, but regulatory approval for generics takes 3-5 years

India does not recognize composition-of-matter patents for many peptides, which means Indian manufacturers can legally produce tirzepatide domestically. Several Indian pharmaceutical companies (Sun Pharma, Dr. Reddy's, Biocon) manufacture tirzepatide for domestic and export markets outside the U.S. and EU.

Medical tourism for tirzepatide is legally complex:

Personal importation for individual use is technically allowed under FDA guidelines if the quantity is for personal use (90-day supply or less), the drug is not available in the U.S., and it's for a serious condition. However, tirzepatide IS available in the U.S. as Mounjaro and Zepbound, which disqualifies it from the personal importation exemption.

Purchasing tirzepatide abroad and bringing it back violates the Federal Food, Drug, and Cosmetic Act. U.S. Customs and Border Protection can seize non-FDA-approved medications at the border.

Traveling to another country for treatment is legal. A patient can receive tirzepatide injections in Mexico, India, or Thailand under local medical supervision. The treatment stays in that country. This is expensive (travel costs exceed medication savings) and impractical for a weekly injection.

The risk-benefit calculus: international tirzepatide is cheaper but carries quality, legal, and safety risks. Counterfeit GLP-1 medications are common in international markets. The WHO reported 200+ incidents of falsified semaglutide in 2023-2024 (WHO Medical Product Alert, 2024). Tirzepatide counterfeits are appearing in the same supply chains.

The FormBlends clinical pattern: what patients ask when supply tightens

Across our provider network, the same question pattern emerges when patients hear about the tirzepatide shortage potentially resolving:

Phase 1 (weeks 1-2 after news): "Should I stockpile compounded tirzepatide before it becomes unavailable?" The answer is no. Compounded tirzepatide has a 60-day beyond-use date after reconstitution. Stockpiling creates waste and doesn't solve the access problem.

Phase 2 (weeks 3-4): "Can I switch to semaglutide and switch back to tirzepatide later?" Yes, but the transition has a 4-to-6-week adaptation window. Patients who switch from tirzepatide to semaglutide often report increased nausea during re-titration. The dual-agonist mechanism (GLP-1 + GIP) is not replicated by semaglutide (GLP-1 only).

Phase 3 (weeks 5-8): "What if I just stop treatment and restart when generics are available?" Weight regain after GLP-1 discontinuation is well-documented. The STEP-1 extension trial showed patients regained two-thirds of lost weight within one year of stopping semaglutide (Wilding et al., JAMA, 2022). Stopping tirzepatide in 2026 and restarting in 2037 means 11 years off treatment. The clinical pattern we observe: patients who stop GLP-1 therapy with the intent to restart rarely do.

Phase 4 (ongoing): "Is there anything else that works?" The honest answer: tirzepatide and semaglutide are the most effective weight-loss medications currently available. Older options (liraglutide, phentermine, naltrexone-bupropion, orlistat) produce 5% to 10% weight loss vs 15% to 22% for GLP-1 agonists (Wilding et al., NEJM, 2021; Jastreboff et al., NEJM, 2022). Bariatric surgery remains more effective than medication for severe obesity but carries surgical risks.

The pattern reveals a gap in patient understanding: the assumption that generic tirzepatide is "coming soon" when the reality is 10+ years away.

When you should NOT wait for generic tirzepatide

Waiting for generic tirzepatide makes sense if:

• You have mild overweight (BMI 27-29) without comorbidities
• You've achieved your goal weight on compounded tirzepatide and are considering maintenance
• You have access to affordable brand-name tirzepatide through insurance
• You're willing to use semaglutide or other GLP-1 options as a bridge

Waiting does NOT make sense if:

• You have obesity (BMI 30+) with comorbidities like type 2 diabetes, hypertension, or sleep apnea
• You're at high cardiovascular risk (prior heart attack, stroke, or heart failure)
• You've failed other weight-loss interventions
• You're delaying treatment hoping for a 2027 or 2028 generic (it won't exist)

The clinical evidence is clear: earlier intervention produces better outcomes. The Look AHEAD trial showed that weight loss in adults with type 2 diabetes reduced cardiovascular events, but the benefit was time-dependent (Look AHEAD Research Group, NEJM, 2013). Waiting 10 years for generic pricing means 10 years of untreated metabolic disease progression.

The cost-benefit calculation: if brand-name tirzepatide costs $12,000/year out-of-pocket and prevents one major cardiovascular event (average cost $50,000 to $100,000), the medication pays for itself in reduced acute care costs. This assumes you're in a high-risk group. For low-risk patients, the calculus is different.

A second consideration: the patent cliff may never produce true generic pricing for peptides. Biosimilar competition historically yields 40% to 60% price reductions, not the 80% to 90% reductions seen with small-molecule generics (Brennan et al., Health Affairs, 2024). A $400/month biosimilar in 2037 is more realistic than a $50/month generic.

The decision tree for choosing treatment now vs later

Start here: Do you have a clinical indication for tirzepatide (BMI 30+, or BMI 27+ with weight-related comorbidity)?

• No → GLP-1 therapy is not appropriate. Focus on lifestyle modification.
• Yes → Continue.

Is brand-name tirzepatide (Mounjaro or Zepbound) covered by your insurance?

• Yes, with affordable copay ($0-$100/month) → Start brand-name now. No reason to wait.
• Yes, but high copay ($200+/month) → Check Eli Lilly savings programs. If still unaffordable, continue.
• No coverage → Continue.

Is compounded tirzepatide currently available and affordable ($200-$400/month)?

• Yes → Start compounded tirzepatide now with a transition plan for when the shortage resolves (likely late 2026). Build the cost of brand-name into your 2027 budget or plan to switch to semaglutide.
• No, or shortage has already resolved → Continue.

Can you afford brand-name out-of-pocket ($1,069/month list price, or $550/month with Lilly savings card)?

• Yes → Start brand-name now.
• No → Continue.

Is semaglutide (Ozempic, Wegovy, or compounded) an acceptable alternative?

• Yes → Start semaglutide. It's 80% as effective as tirzepatide for weight loss and may remain available compounded longer.
• No, or semaglutide is also unavailable/unaffordable → Continue.

Are you willing to use older weight-loss medications (phentermine, naltrexone-bupropion, orlistat) or consider bariatric surgery?

• Yes → Discuss with your provider. These are less effective than GLP-1 agonists but better than no treatment.
• No → You're choosing to wait. Set a calendar reminder for 2035 to check biosimilar tirzepatide availability. In the meantime, focus on lifestyle modification and metabolic monitoring.

The decision tree reveals the hard truth: for most patients without insurance coverage, there is no good option between "pay $550 to $1,069/month now" and "wait until 2037." The middle ground (compounded tirzepatide) is disappearing.

FAQ

When will tirzepatide be available as a generic? The earliest possible date is December 2036, when Eli Lilly's composition-of-matter patent expires. Realistically, biosimilar tirzepatide will launch in 2037 or 2038 after FDA approval. True generic versions may not exist until the 2040s due to the complexity of peptide manufacturing.

Why is compounded tirzepatide legal if patents protect it? Compounded tirzepatide is legal under a temporary FDA exemption for drugs in shortage. The exemption allows compounding pharmacies to produce copies without violating patent law. This exemption ends when the FDA removes tirzepatide from the shortage list, likely in late 2026 or early 2027.

What happens to compounded tirzepatide when the shortage ends? Compounding pharmacies must stop producing tirzepatide within 60 to 90 days of the FDA removing it from the shortage list. Patients on compounded versions will need to switch to brand-name Mounjaro or Zepbound, transition to a different medication, or discontinue treatment.

Will tirzepatide be cheaper in 2037 when patents expire? Yes, but not as cheap as small-molecule generics. Biosimilar tirzepatide will likely cost 40% to 60% less than brand-name pricing, bringing monthly costs from $1,069 to $400 to $650. True generic pricing ($50 to $150/month) is unlikely due to manufacturing complexity.

Can I buy generic tirzepatide from other countries? Generic tirzepatide is available in countries like India and China where patents don't apply, but importing it to the U.S. is illegal. The FDA prohibits personal importation of medications that are already available domestically. Counterfeit and substandard products are common in international markets.

Is biosimilar tirzepatide the same as generic tirzepatide? No. Biosimilars are "highly similar" to the original drug but not identical due to manufacturing differences. They require separate FDA approval and clinical trials. Generics are chemically identical copies. Tirzepatide will have biosimilars, not true generics.

How long does it take for generic drugs to reach the market after patent expiration? For small-molecule drugs, generics typically launch the day patents expire. For biologics and peptides, biosimilars take 24 to 36 months after patent expiration due to FDA approval timelines. Expect biosimilar tirzepatide in 2037 or 2038.

Will insurance cover tirzepatide better when generics are available? Likely yes. Insurance coverage typically expands when biosimilar competition lowers prices. However, coverage policies in 2037 will depend on obesity treatment guidelines and cost-effectiveness analyses at that time. Current restrictive coverage may persist.

Can I stockpile compounded tirzepatide before it becomes unavailable? No. Compounded tirzepatide has a 60-day beyond-use date after reconstitution. Stockpiling creates waste and doesn't solve long-term access problems. Focus on building a transition plan instead.

Should I start tirzepatide now or wait for generics? If you have a clinical indication (BMI 30+, or BMI 27+ with comorbidities), starting now is medically appropriate. Waiting 10+ years for generic pricing means a decade of untreated metabolic disease. If cost is prohibitive, discuss alternative GLP-1 options or older weight-loss medications with your provider.

What is Eli Lilly doing to make tirzepatide more affordable before patent expiration? Eli Lilly offers savings programs that reduce costs to $25/month for insured patients and $550/month for uninsured patients. These programs are subject to eligibility requirements and may change. The company has not announced plans for an authorized generic.

Are there any legal challenges to Eli Lilly's tirzepatide patents? As of April 2026, no Paragraph IV patent challenges have been filed by generic manufacturers. Patent challenges typically begin 3 to 4 years before expiration, so expect potential litigation starting in 2032 or 2033.

Sources

1. Jastreboff AM et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022.
2. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
3. Wilding JPH et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide. JAMA. 2022.
4. Mulcahy AW et al. Biosimilar Cost Savings in the United States. RAND Corporation. 2021.
5. Socal MP et al. Biosimilar Uptake and Price Changes Following Adalimumab Biosimilar Launches. JAMA Health Forum. 2022.
6. Brennan TA et al. Biosimilar Price Competition in the United States. Health Affairs. 2024.
7. Look AHEAD Research Group. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. New England Journal of Medicine. 2013.
8. Davies MJ et al. Gastric Emptying Effects of Tirzepatide vs Placebo. Diabetes Care. 2023.
9. U.S. Patent and Trademark Office. Patent 9,624,267 (tirzepatide composition of matter). 2017.
10. U.S. Patent and Trademark Office. Patent 10,525,109 (tirzepatide formulation). 2019.
11. FDA Drug Shortages Database. Tirzepatide shortage status. Accessed April 2026.
12. FDA Warning Letters Database. Compounding pharmacy violations 2024-2025. Accessed April 2026.
13. World Health Organization. Medical Product Alert N°4/2024: Falsified semaglutide. 2024.
14. Eli Lilly and Company. Q4 2025 Investor Call Transcript. February 2026.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Ozempic and Wegovy are registered trademarks of Novo Nordisk. Victoza and Saxenda are registered trademarks of Novo Nordisk. Humira is a registered trademark of AbbVie Inc. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.